Related Experiment Video
Updated: Jun 19, 2026

Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Cancer risk evaluation in psoriasis: in search of the Holy Grail?
Carle F Paul1, Pierre-Antoine Gourraud
1Paul Sabatier University, Toulouse, France. paul.c@chu-toulouse.fr
Abstract:
Benefit-risk assessment of systemic treatment in psoriasis is a dynamic process. Long-term safety of psoriasis therapies has been questioned, with the spectrum of systemic immunosuppression potentially leading to increased cancer risk. In this issue, Brauchli et al. report on a population-based analysis of cancer risk in a large cohort of psoriasis patients, most of whom had not been treated with systemic agents. The study prepares the ground for future prospective long-term cohort studies in psoriasis patients treated with systemic therapies, including biological agents.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Survival Analysis
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
